Cogent Biosciences, Inc. (COGT)
Free
No email, no account, no signup.
Pulling latest news for Cogent Biosciences, Inc.…
Bull
Bear
Want the why behind the signal? Get the deep 4-model report — full bull/bear, dated catalysts, dilution risk, weekly refresh. $4.99.
Get the deep 4-model report – $4.99
Order analysis – $4.99
Not satisfied? Get your money back within 7 days — no questions asked.
7-day money-back guarantee · No lock-in period · Secure payment via Stripe
Exchange
NASDAQ
Type
Biotech
Sector
Precision therapies for genetic diseases
Market Cap
$6.3B
We're already tracking Cogent Biosciences, Inc. — here are the latest events we've registered
Recent News
- On May 5, 2026, Cogent reported Q1 2026 results with $866.4 million in cash and announced the submission of a New Drug Application for bezuclastinib in GIST. The company is preparing for potential commercial launches in the second half of 2026, with a PDUFA date of December 30, 2026, for systemic mastocytosis. Detailed clinical results are scheduled for oral presentation at the ASCO Annual Meeting on May 30, 2026.
Want to know how this news affects Cogent Biosciences, Inc.? Order the analysis.
Order analysis – $4.99
What you get
A complete express analysis — not just a signal. Delivered as a webpage in your account.
- Signal: BUY / HOLD / SELL — with clear reasoning
- Sentiment score 1–10 based on news, reports, and market data
- Risk score 1–10 (dilution, jurisdiction, execution)
- Bull case: 3–5 specific points with evidence (e.g. "Oversold after panic-reaction to security news, opening a technical bounce setup")
- Bear case: 3–5 specific risks (e.g. "Extreme uncertainty around the security situation in Sinaloa after tragic events")
- Upcoming catalysts with dates
- Assessment of dilution risk
Want to see what a finished analysis looks like?
View a sample analysis
This is a real Firelda analysis. Your analysis of Cogent Biosciences, Inc. will be delivered in the same format.
Not satisfied? Get your money back within 7 days — no questions asked.
The information on this page does not constitute investment advice. AI-generated analyses may contain errors. Always conduct your own research before making investment decisions. Firelda.ai is not responsible for any potential losses.